{"id":449601,"date":"2026-02-05T21:15:35","date_gmt":"2026-02-05T20:15:35","guid":{"rendered":"https:\/\/medizinonline.com\/new-strategy-in-the-fight-against-obesity-and-t2d\/"},"modified":"2025-11-21T17:42:59","modified_gmt":"2025-11-21T16:42:59","slug":"new-strategy-in-the-fight-against-obesity-and-t2d","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/new-strategy-in-the-fight-against-obesity-and-t2d\/","title":{"rendered":"New strategy in the fight against obesity and T2D"},"content":{"rendered":"\n

The treatment of obesity and type 2 diabetes is increasingly shifting to newer incretin drugs, including GLP1 receptor agonists (single agonists such as semaglutide) and GIP- and GLP1-RA (dual agonists such as tirzepatide). However, there is still a need for stronger and more selective therapies with a better effect and minimized side effect profile. In the mouse model, the quintuple agonist GLP1:GIP:PanPPAR shows promise. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

The treatment of obesity and type 2 diabetes is increasingly shifting to newer incretin drugs, including GLP1 receptor agonists (single agonists such as semaglutide) and GIP- and GLP1-RA (dual agonists……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":449610,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Development of a quintuple agonist","footnotes":""},"category":[11513,11384,11442,11548,11503],"tags":[86609,86715,86721,86722,86718,16579,12390,86726,17444,28909,80048,72410,12042],"powerkit_post_featured":[],"class_list":["post-449601","post","type-post","status-publish","format-standard","has-post-thumbnail","category-congress-reports","category-endocrinology-and-diabetology","category-pharmacology-and-toxicology","category-rx-en","category-studies","tag-easd-2025","tag-gip-glp1-ra","tag-glp1-receptor-agonists-2","tag-glp1gippanppar","tag-incretin-medication","tag-mouse-model","tag-obesity","tag-quintuple-agonist","tag-semaglutide-en-2","tag-side-effect-profile","tag-t2d-en","tag-tirzepatide","tag-type-2-diabetes","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-12 23:35:39","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":449635,"slug":"nouvelle-strategie-de-lutte-contre-lobesite-et-le-dt2","post_title":"Nouvelle strat\u00e9gie de lutte contre l'ob\u00e9sit\u00e9 et le DT2","href":"https:\/\/medizinonline.com\/fr\/nouvelle-strategie-de-lutte-contre-lobesite-et-le-dt2\/"},"it_IT":{"locale":"it_IT","id":449626,"slug":"nuova-strategia-nella-lotta-contro-lobesita-e-la-t2d","post_title":"Nuova strategia nella lotta contro l'obesit\u00e0 e la T2D","href":"https:\/\/medizinonline.com\/it\/nuova-strategia-nella-lotta-contro-lobesita-e-la-t2d\/"},"pt_PT":{"locale":"pt_PT","id":449617,"slug":"nova-estrategia-na-luta-contra-a-obesidade-e-a-doenca-de-alzheimer","post_title":"Nova estrat\u00e9gia na luta contra a obesidade e a doen\u00e7a de Alzheimer","href":"https:\/\/medizinonline.com\/pt-pt\/nova-estrategia-na-luta-contra-a-obesidade-e-a-doenca-de-alzheimer\/"},"es_ES":{"locale":"es_ES","id":449607,"slug":"nueva-estrategia-en-la-lucha-contra-la-obesidad-y-la-t2d","post_title":"Nueva estrategia en la lucha contra la obesidad y la T2D","href":"https:\/\/medizinonline.com\/es\/nueva-estrategia-en-la-lucha-contra-la-obesidad-y-la-t2d\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/449601","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=449601"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/449601\/revisions"}],"predecessor-version":[{"id":449612,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/449601\/revisions\/449612"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/449610"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=449601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=449601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=449601"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=449601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}